πŸ›’ 0
Weight Loss / GLP-1 / GIP

Tirzepatide

Dual GIP & GLP-1 Receptor Agonist (Molecular Mass: 4813.5 g/mol)

ZAR 1,900.00
Unit Cost: ZAR 190.00 / mg
❄️ In Stock β€” Ready for Cold-Chain Dispatch
Loading shipping schedule...
Select Concentration:
Allocation Quantity:
βœ“ >99.2% HPLC Purity
🧊 Cold-Chain Courier
πŸ”’ Secure EFT Payment
πŸ‡ΏπŸ‡¦ Synthesised in JHB

Batch Integrity Certificate

Analysis performed by Johannesburg Chemical Synthesis Lab Environment

HPLC: 99.54%

Batch ID

#TIR-2026-B10

CAS Number

2023788-19-2

Appearance

Lyophilized White Powder

Validation Date

May 2026

Clinical Dossier: Tirzepatide

Comprehensive pharmacological data, standardized research protocols, and clinical efficacy metrics for our >99% HPLC verified dual-agonist formulations.

🧬 Pharmacological Profile

Tirzepatide is a next-generation linear peptide engineered as a synthetic "twincretin"β€”a single molecule that functions as a dual agonist at both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This structural integration yields synergistic downstream therapeutic effects far exceeding single-agonist capabilities.

The addition of GIP receptor activity alters the regulatory pathway entirely: while GLP-1 aggressively targets central appetite suppression in the hypothalamus and delays gastric emptying, GIP directly modifies metabolic performance within peripheral white adipose tissues. This enhances lipid buffering, improves insulin sensitivity, and counteracts the compensatory decrease in basic energy expenditure typically observed during severe caloric deficits.

πŸ“Š Observed Clinical Efficacy

In global multi-phase clinical trial tracking (SURPASS regimes), Tirzepatide demonstrated an unprecedented metabolic performance profile. Test subjects consistently surpassed traditional single-agonist targets, achieving dose-dependent mean body weight reduction thresholds of up to 20.9% over a standard 72-week profile.

The molecular synergy targets metabolic efficiency directly. It accelerates the clearance of visceral fat deposits, dramatically controls fasting plasma glucose values, and modulates structural lipid panels with a lower gastrointestinal side-effect profile compared to historical single-receptor weight management agents.

⏱️ Standardized Research Protocol

A conservative, step-wise escalation titration timeline is mandatory to preserve receptor binding sensitivity and minimize transient gastrointestinal adjustments.

Phase Duration Dosage (Weekly)
Initiation Weeks 1 - 4 2.5 mg
Titration 1 Weeks 5 - 8 5.0 mg
Titration 2 Weeks 9 - 12 7.5 mg
Titration 3 Weeks 13 - 16 10.0 mg
Escalation Weeks 17 - 20 12.5 mg
Maintenance Week 21+ 15.0 mg

πŸ§ͺ Reconstitution & Handling

Tirzepatide is delivered as a fragile lyophilized powder matrix structure. Reconstitution must be completed prior to lab execution using sterile Bacteriostatic Water (BAC). It remains highly vulnerable to structural chain degradation if subjected to mechanical shearing forces.

  • Direct the stream of BAC fluid down the inner glass vial wall slowly.
  • Do not shake the vial. Roll the base slowly between open palms until complete clear solute configuration is achieved. Store between 2Β°C and 8Β°C immediately.

πŸ“ Reconstitution Math (10mg):

Adding 2mL of Bacteriostatic Water to a 10mg vial yields a concentration of 5.0mg per 1mL.

(e.g., A 2.5mg starting dose equates to 50 units / 0.5mL on a standard U-100 insulin syringe).

⚠️ Research Requisition Disclaimer (SAHPRA Compliance)

All synthetic peptides and clinical compounds supplied by Slim Science are synthesized strictly for laboratory evaluation, biochemical profiling, and in-vitro research parameters. These formulations have not been evaluated by the South African Health Products Regulatory Authority (SAHPRA) and are not registered under the Medicines and Related Substances Act, 101 of 1965. They are not intended for human diagnostic, therapeutic, or clinical intervention.